PerkinElmer Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates through two segments, Human Health and Environmental Health. The company was founded in 1931 and is based in Waltham, Massachusetts.
PKI Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Perkinelmer Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Perkinelmer Inc ranked in the 37th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for PKI, they are:
Interest coverage, a measure of earnings relative to interest payments, is 5.62 -- which is good for besting 56.24% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
89% of the company's capital comes from equity, which is greater than 71.18% of stocks in our cash flow based forecasting set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Perkinelmer Inc? See CRL, MGLN, MMSI, IART, and ITGR.
PerkinElmer ([[PKI]] +0.3%) said its New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization ((EUA)) from the FDA to test individuals without symptoms or other reasons to suspect COVID-19 infection.Previously, the FDA issued EUA to allow sample pooling with PKI's New Coronavirus Nucleic Acid Detection Kit to increase the number of individuals...
PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to test individuals without symptoms or other reasons to suspect COVID-19 infection.